사이언처 홀딩스SCNX 주가

Scienture Eric Sherb Resigns As CFO Effective May 26, 2026; Narasimhan Mani Appointed As Interim CFO Effective May 26, 2026

-SEC Filing

♻️ 재탕[8-K] 중대 사건 — 8-K

[8-K] 중대 사건 — 8-K

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

COMMACK, NY, May 18, 2026 -- SCIENTURE HOLDINGS, INC. , a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians...

Scienture Holdings Q1 EPS $(0.08) Beats $(0.22) Estimate, Sales $56.325K Up From $10.258K YoY

Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.22) by 63.64 percent. This is a 75.76 percent increase over losses of $(0.33) per share

Scienture Holdings: Q1 Earnings Snapshot

COMMACK, N.Y. — COMMACK, N.Y. — Scienture Holdings, Inc. on Friday reported a loss of $3.4 million in its first quarter. On a per-share basis, the Commack, New York-based company said it had...

[10-Q] 분기 실적 — 10-Q

SCIENTURE HOLDINGS Secures $11M In Non-Dilutive Debt Financing Through Note Purchase Agreement With Institutional Investor

Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatmentFinancing also drives early-

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatment Financing also...

USPTO Issued SCIENTURE HOLDINGS U.S. Patent No. 12,605,365, Titled "Losartan Liquid Formulations and Methods of Use,"

U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI™ as the first FDA-approved ready-to-use oral suspension